Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech Limited has notified BSE about its 33rd Annual General Meeting (AGM) scheduled for September 29, 2025 at 4:00 PM via video conferencing, along with the Annual Report for FY 2024-25. The AGM will consider key items including adoption of audited financials, re-appointment of three retiring directors, and appointment of three Whole-time Directors and one Independent Director for five-year terms. The company is proposing to increase its authorized share capital from Rs. 65 crore to Rs. 85 crore (8.5 crore equity shares of Rs. 10 each) to facilitate a Rights Issue of Rs. 49.90 crore, while rescinding the earlier Rs. 75 crore hike passed at the 32nd AGM. Shareholders will also be asked to approve material related party transactions worth up to Rs. 25 crore each with six subsidiaries, appointment of a new Secretarial Auditor for five years, and disinvestment from Dindigul Farm Product Limited along with reclassification of IBL from 'Promoter' to 'Public' category in that subsidiary. Notable management changes during the year include a new CFO (Dhinakaran Rajagopal from April 4, 2025) replacing Vinayaka Bodala, and the exit of Company Secretary V Santhanakrishnan on June 13, 2025.
For shareholders, the key takeaways are a planned Rights Issue of Rs. 49.90 crore (which may dilute existing holdings) and a proposed exit from Dindigul Farm Product Limited. The increased related party transaction limits with subsidiaries signal continued inter-group activity, and the multiple board appointments reflect stable governance. The stock price may react to clarity on the Rights Issue price and the value realized from the Dindigul disinvestment.